Notice NOT-NS-22-052 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-043 from the NIH Guide for Grants and Contracts

Notice NOT-AG-21-040 from the NIH Guide for Grants and Contracts

Notice NOT-NS-22-056 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-050 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-088 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites qualified academic and research institutions to apply for funding to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and private nonprofit institutions of higher education as well as from non-profit research organizations. Applications from both research-intensive institutions and Institutions of Emerging Excellence in biomedical research from all geographic regions in the nation are strongly encouraged. NIH recognizes the importance of all institutions of higher learning in contributing to the nations research capacity. The goal of this FOA is to upgrade or create novel biomedical research infrastructure to strengthen biomedical research programs. Each project is expected to provide long-term improvements to the institutional research infrastructure. Targeted projects are the construction or modernization of core facilities and the development of other infrastructure serving an institution-wide research community on a shared basis.

Funding Opportunity RFA-DK-21-020 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to establish a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D). Individuals with IAH are often excluded from clinical trials and this omission contributes greatly to a lack of knowledge regarding the clinical characteristics which determine or predict an individuals ability to restore hypoglycemic awareness. New technologies such as continuous glucose monitors (CGM) and closed loop systems (i.e. artificial pancreas) have been shown to reduce hypoglycemic events. However, despite a reduction in hypoglycemic events, restoration of hypoglycemia awareness does not occur in all individuals and the effects on improving the counter-regulatory responses are not known. The goals of the clinical consortium will be to 1) determine if state-of-the-art diabetes technology to optimize HbA1c while minimizing hypoglycemia can restore awareness of hypoglycemia and improve counter-regulatory responses in individuals with T1D; 2) identify the magnitude and duration of time in range (TIR), time spent in hypoglycemia or other CGM metrics that are associated with restoration of awareness of hypoglycemia; and 3) validate current self-report assessments of impaired awareness of hypoglycemia with physiological measurements. It is expected that state of the art techniques such as hypoglycemic, hyperinsulinemic clamps (with or without stable isotopes) for the measurement of counter-regulatory responses and endogenous glucose production will be utilized to determine restoration of awareness and validate self-report assessments.

Funding Opportunity RFA-DK-21-036 from the NIH Guide for Grants and Contracts. This FOA invites applications for a Biostatistics Research Center (BRC) to participate in a clinical consortium to determine the factors that contribute to the heterogeneity in the restoration of impaired awareness of hypoglycemia (IAH) and improved counter-regulatory responses in adult individuals with Type 1 Diabetes (T1D) and impaired awareness of hypoglycemia (IAH). A separate FOA (RFA-DK-21-020) invites Clinical Centers to 1) determine if the most up-to-date diabetes technology to optimize HbA1c while minimizing hypoglycemia can restore awareness of hypoglycemia and improve counter-regulatory responses in individuals with T1D and IAH; 2) identify the magnitude and duration of time in range (TIR), time spent in hypoglycemia or other CGM metrics that are associated with restoration of awareness of hypoglycemia; and 3) validate current self-report assessments of impaired awareness of hypoglycemia with physiological measurements derived from state of the art metabolic assessments.

*About Invenra: * We are a rapidly expanding and well-funded biotechnology company focused on employing cutting edge protein engineering and multi-specific…
From Indeed - Mon, 03 Jan 2022 23:19:11 GMT - View all Madison, WI jobs

Notice NOT-MH-22-105 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-22-171 from the NIH Guide for Grants and Contracts. Efforts are underway to develop a safe and effective vaccine to protect people from acquiring HIV ultimately reducing the number of new infections and ending the epidemic. However, the subject of vaccines remains contentious, and COVID-19 has heightened the conversation. There are multiple messages circulating both for and against vaccines and a growing number of skeptics appear to be making decisions about vaccines based on misinformation. This initiative will advance research on communication factors and strategies that will be crucial for successful public understanding, acceptance, and uptake of future vaccines that protect against HIV.

Funding Opportunity RFA-MH-22-170 from the NIH Guide for Grants and Contracts. Efforts are underway to develop a safe and effective vaccine to protect people from acquiring HIV ultimately reducing the number of new infections and ending the epidemic. However, the subject of vaccines remains contentious, and COVID-19 has heightened the conversation. There are multiple messages circulating both for and against vaccines and a growing number of skeptics appear to be making decisions about vaccines based on misinformation. This initiative will advance research on communication factors and strategies that will be crucial for successful public understanding, acceptance, and uptake of future vaccines that protect against HIV.

Funding Opportunity RFA-DA-22-049 from the NIH Guide for Grants and Contracts. This FOA seeks applications for one Modeling and Economic Resource Center to support the HEAL D2A Innovation Projects. This center will provide expertise in a variety of simulation modeling and economic analyses and methods; utilize agent-based, predictive, geospatial or other simulation models to inform Innovation Project grantees about the potential public health impact of implementing different interventions, to support local implementation decisions; support the Innovation Projects in assessing costs and cost benefit associated with selected service delivery changes; develop costing tools that can be utilized by Innovation Grants to inform local decisions about the selection of interventions; and conduct original research applying state-of-the-art economic and simulation modeling expertise to understand and address the overdose crisis. This FOA runs in parallel with a set of companion FOAs supporting the other components of the HEAL D2A Program.

Funding Opportunity RFA-DA-22-050 from the NIH Guide for Grants and Contracts. This FOA solicits applications for one HEAL D2A Research Adoption Support Center to provide coordination and implementation support for the HEAL D2A Innovation Projects. The Centers primary purpose is to support funded projects in the selection and deployment of evidence-based practices to address identified needs. The Research Adoption Support Center will also provide logistical coordination for the initiative, engage key stakeholders, conduct rapid-turnaround studies in response to stakeholder-identified priorities, and conduct a formative evaluation of the HEAL D2A Program. This FOA runs in parallel with a set of companion FOAs supporting the other components of the HEAL D2A Program.

Funding Opportunity RFA-DA-22-051 from the NIH Guide for Grants and Contracts. As part of the NIH HEAL Initiative, the National Institute on Drug Abuse (NIDA) is releasing a set of interrelated RFAs to create the HEAL Data2Action (D2A) Program, a coordinated effort to promote the synthesis and real-world application of existing data to guide and monitor improvements in service delivery to prevent or treat opioid use disorder (OUD) and pain. Collectively, these projects will address gaps in the delivery of evidence-based practices in each of the four pillars of the HHS Overdose Prevention Strategy: primary prevention, harm reduction, treatment of opioid use disorder, and recovery support. Separate FOAs are being issued to support multiple HEAL D2A Innovation Projects (RFA-DA-22-051); one HEAL D2A Data Infrastructure Support Center (RFA-DA-22-052); one HEAL D2A Research Adoption Support Center (RFA-DA-22-050); and one HEAL D2A Economics and Modeling Resource Center (RFA-DA-22-049). It is imperative that prospective applicants read all of these related RFAs to better understand the intended purpose and structure of the HEAL D2A Program. This FOA solicits applications for HEAL D2A Innovation Projects, which are phased awards intended to support local efforts, either within a single system or in cross-sector partnerships, to improve utilization of data to drive prediction and real-time proactive responses to the overdose crisis.

Funding Opportunity RFA-DA-22-052 from the NIH Guide for Grants and Contracts. This FOA seeks applications for a single Data Infrastructure Support Center to support the HEAL Data-to-Action (D2A) Innovation Grants. Key activities for this Support Center would include (1) providing tailored data infrastructure and resources to support the Innovation Grants in identifying, merging, and analyzing existing records or data systems to forecast service needs or gaps and to monitor improvements resulting from strategic implementation of new interventions; (2) facilitating access to key datasets that may be of broad interest to the D2A grantees; (3) providing data visualization support to enhance the utility of local data for decision-makers; and (4) compiling a library of measures that can be used across projects to measure service delivery and outcomes, e.g., along the opioid care cascade. This FOA runs in parallel with a set of companion FOAs supporting the other components of the HEAL D2A Program.

Funding Opportunity RFA-ES-22-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit grant applications that propose to: (1) support the maintenance and resource infrastructure enrichment for existing Environmental Epidemiology Cohorts (EECs) and to (2) enrich data management and data sharing activities to promote widespread data sharing and scientific collaborations to be inclusive of under-resourced minority-serving institutions and under-represented minority researchers. The ultimate goal is to maintain and maximize NIEHS cohort investments within the environmental epidemiology community by improving data collection on under-represented populations in environmental health studies, strengthening workforce diversity and promoting greater scientific collaboration.

£40,000-£50,000 depending on skills and experience: General Bioinformatics: Creative use of bioinformatics data coupled with scientific insight, you will provide novel information for genomics and target discovery projects. Reading, Berkshire

Funding Opportunity RFA-CA-22-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Funding Opportunity RFA-CA-22-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.